Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise
ST. PAUL, Minn. (AP) — Uber and Lyft plan to keep operating in Minnesota after the state Legislature2024-05-21Olivia Dunne teases fans on social media with multi
Olivia Dunne has started to charge fans for content, as the LSU gymnast is offering 200 messages for2024-05-21White Sox outright reliever Deivi García to Triple
CHICAGO (AP) — The Chicago White Sox outrighted reliever Deivi García to Triple-A Charlotte on Thurs2024-05-21- Jay Leno and his wife of nearly 44 years, Mavis Nicholson Leno, enjoyed a date night at the Hollywoo2024-05-21
Mystery artist who erected signs comparing pothole
A defiant resident infuriated by the potholes in their road has taken revenge on the council by erec2024-05-21Barry Keoghan enjoys the spoils of his superstardom by watch shopping on Bond Street
Barry Keoghan is Hollywood's current star du jour. And the Saltburn star, 31, is clearly using the s2024-05-21
atest comment